Thus, we demonstrate that treatment with BCR pathway inhibitors clearly enhances AID-dependent mutagenesis in specific off-target genes, and this increased mutational activity does not correlate with CLL-relevant clinical features. This evidence concerns the gene AICDA and B-cell chronic lymphocytic leukemia.